butabarbital decreases results of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Coadministration of CYP3A4 inducers may lessen sufentanil degrees and efficacy, probably precipitating withdrawal syndrome in sufferers who may have formulate